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Introduction. We sought to determine the association between HIV-induced immunosuppression, virologic correlates, and
vulvovaginal candidiasis (VVC). Methods. This is a retrospective cohort study, where HIV infected and uninfected women were
studied with VVC being the primary outcome. Ninety-seven HIV-infected and 101 HIV-uninfected women were enrolled between
June andDecember 2011. Cases of VVCwere confirmed. HIVRNA loadwas determined by RT-PCR andCD4 counts were obtained
from medical records. Results. Fifty-two of 97 (53.6%) HIV-infected and 38/101 (37.6%) HIV-uninfected women were diagnosed
with VVC (𝑃 = 0.032).The relative risk for VVC amongst HIV-infected patients was 1.53 (95%CI: 1.04–2𝑃 = 0.024). Cases of VVC
increased at CD4+T cell count below 200 cells/mm3 (𝑃 < 0.0001) and plasmaHIVRNA load above 10 000 copies/mL (𝑃 < 0.0001).
VVC was associated with increased genital shedding of HIV (𝑃 = 0.002), and there was a linear correlation between plasma HIV
load and genital HIV shedding (𝑟 = 0.540; 𝑅2 = 0.292; 𝑃 < 0.0001). Women on HAART were 4-fold less likely (𝑃 = 0.029) to
develop VVC.Conclusion. CD4 counts below 200 cells/mm3 and plasmaHIV loads ≥10 000 copies/mLwere significantly associated
with VVC.
1. Introduction
Symptomatic vulvovaginal candidiasis (VVC) is caused by
a number of species belonging to the genus Candida which
are commensal fungi of the gastrointestinal tract and vagina.
Candida albicans has been reported as the cause of symp-
tomatic VVC in 85%–95% of cases, whilst C. glabrata rep-
resents the most common cause of nonalbicans candida
vaginitis [1].
Whilst 75% of healthy women develop symptomatic VVC
at least once during their reproductive age, it is estimated that
5%–8%of women develop recurrent vulvovaginal candidiasis
(RVVC). The latter is defined as the occurrence of four or
more episodes of symptomatic VVC per year [1].
In HIV infected patients, whilst oroesophageal candidi-
asis is known to appear at any time during the course of
progression of HIV infection, symptomatic VVC develops
significantly later [2]. It has been shown that oroesophageal
candidiasis occurs as a result of the loss of mucosal and
systemic cell-mediated immunity, while animal studies, in
vitro experiments, and clinical trials indicate that systemic
cell-mediated immunity does not play a protective role
against candida vaginitis [3–5].
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Cross-sectional studies of women attending antenatal
clinics and family planning clinics in South Africa over the
past 20 years showed a weighted average prevalence of 26%
for symptomatic VVC [6–8]. Among these studies, many
have been conducted in KwaZulu-Natal where there is a high
prevalence of HIV in South Africa. Data from the national
population-based survey conducted in 2008 estimated HIV
prevalence in young people aged 15–24 years to be 15.3% (95%
CI 11.8–19.7) in the province of KwaZulu-Natal compared to
the national estimate of 8.7% (95% CI 7.2–10.4) [9].
Ramjee et al. reported the prevalence of 36.1% and 45.7%
for symptomatic VVC, respectively, amongHIV negative and
HIV positive sex workers in KwaZulu-Natal [7]. In 2011,
during a nested control analysis from a prospective trial of 1
404 women (716 HIV infected compared with 688 HIV non-
infected) over a 2-year period in KwaZulu-Natal, Sebitloane,
Moodley, and Esterhuizen reported on symptomatic VVC as
being significantly more prevalent amongmore HIV infected
than uninfected women (39.2% versus 30%; RR = 1.31 (1.08–
1.59); 𝑃 = 0.006) [8].
The aim of this study was to determine predictors of
symptomatic VVC in HIV infected women.
2. Materials and Methods
2.1. Patients and Sampling Strategy. This is a retrospective
cohort study design. Consecutive consenting female patients
attending Umlazi D clinic, a primary healthcare facility
in KwaZulu-Natal, were recruited between June 2011 and
December 2011. Presentation with lower genital tract signs
and symptoms was one of the eligibility criteria as depicted
in Figure 1.
A standardized questionnaire was used to collect patient
demographic information, history of STIs and treatment
thereof over the past 3months, condomutilization behaviour,
and prior knowledge of HIV serostatus. HIV positive women
were further questioned about receiving HAART, and this
was confirmed by a review of the medical records.
CD4 counts were obtained frompatients’ medical records
and were not older than 3 months. Blood and genital
secretions for measurement of HIV viral loads were collected
from patients at recruitment.
Patients were invited to participate in the study if they
had signs and symptoms of vaginal discharge syndrome. All
patients were treated syndromically as per standard of care
STI treatment in South Africa. The study was approved by
the Biomedical Research Ethics Committee of the University
of KwaZulu-Natal (Ref. BE 224/11). Consent forms were
signed by all participants and confidentiality was maintained
throughout the study.
2.2. Specimen Collection and Processing. One cervical and
two vaginal swabs (Probetec swabs, Becton Dickinson,
Sparks, Maryland, USA) were used. The two vaginal swabs
collected material from the anterior and posterior fornix,
respectively. A smear was made on a glass slide using the
latter, and the former as well as the cervical swab was placed
in a sterile dry container. A vaginal tampon (8Ks, Tampax
Regular Compak) was thereafter inserted into the vagina and
removed after 3minutes.Thiswas placed in a sterile container
with 10mL of phosphate buffered saline (PBS; Oxoid Limited
Basingstoke,Hampshire,UK) (pH=6.9). Blood sampleswere
collected into ethylenediaminetetraacetic acid (EDTA) and
non-EDTA containing tubes.
All specimens were kept in a cooler box with ice awaiting
transportation (within 4 hours) to the Infection Prevention
and Control, Nelson R Mandela School of Medicine, UKZN.
The anterior fornix vaginal swab was used to inoculate
Sabouraud dextrose agar with chloramphenicol (BBL Becton
Dickinson) and incubated at 29∘C for 48 h. The relative
vaginal fungal burden was estimated as previously described
[10].
The smear was stained using Gram’s method and evalu-
ated by two independentmicroscopists for bacterial vaginosis
(BV) using Nugent’s score [11]. Discrepancies were evaluated
by an independent medical microbiologist.
The cervical swabwas used for the detection ofChlamydia
trachomatis and Neisseria gonorrhoeae using a strand dis-
placement amplification technology (Becton Dickinson Pro-
betec Assays, Sparks, Maryland, USA) method as previously
described [12]. DNA of Mycoplama genitalium, Trichomonas
vaginalis, and herpes simplex virus type 2 was obtained using
QIAamp DNAmini kits (Qiagen Ltd., Chatsworth, CA) [12].
An in-house PCR method for amplification was used as
previously described [12–14].The amplified PCR product was
analyzed by gel electrophoresis.
Vaginal fluid was expressed from vaginal tampon using
an autoclaved wooden tongue depressor and filtered through
a 0.22𝜇m Costar Spin-X cellulose acetate filter membranes
(Sigma) and used for quantifying HIV viral load in genital
secretions.
2.3. Diagnostic Criteria of Symptomatic Vulvovaginal Candidi-
asis and VVC Colonization. The diagnosis of symptomatic
VVC was based on a combination of clinical and laboratory
criteria (evidence level III, recommendation grade B) as
described by the European (IUSTI/WHO) guideline on the
management of vaginal discharge, 2011 [10].
Symptoms suggestive of symptomatic VVC included vul-
val pruritus/itching, vulval soreness, superficial dyspareunia,
and/or malodorous vaginal discharge. Signs included vulval
erythema, vulval oedema, fissures, excoriation, or thick curdy
vaginal discharge.
In addition to the self-reported above symptoms and
observation of signs suggestive of VVC in physical exam-
ination, cases of symptomatic VVC were confirmed if one
of the following criteria was fulfilled: (i) a positive Gram-
stain preparation with budding yeasts, pseudohyphae, and/or
hyphal forms; (ii) positive culture with either moderate (10–
99 colonies per plate) or heavy candida growth (>100 colonies
per plate).
Participants without symptomatic VVC were defined
as (i) patients whose genital specimens had a negative
microscopy result for yeasts, pseudohyphae, and/or hyphal
forms of candida together with negative culture; (ii) patients
whose genital specimens had a negative microscopy result
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 for laboratory investigations (N=198)
VVC infection)
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infection): N = 38
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absence of yeasts in
microscopy and
culture: N = 63
Evaluation for multiple comparisons
- Women aged ≥18 years
- Presented with signs and symptoms suggestive
- Known or unknown HIV status
- Consenting to participate (with sample
- History taking and physical examination for
- Collection of cervicovaginal and blood specimens
- Laboratory diagnosis of LGTIs (including
- Confirmation of HIV status
- CD4+ T cell counts and plasma/genital HIV viral
collection and HIV testing) (N = 200)
Figure 1: Selection criteria and characterization of the study population by HIV groups.
for yeasts, pseudohyphae, and/or hyphal forms of candida
together with light candida growth (<10 colonies per plate).
The latter was considered to indicate vaginal candida colo-
nization rather than infection.
2.4. HIV Testing and Definitions of HIV-Induced Immuno-
suppression. Initial HIV test was performed in the clinic by
a trained research nurse on blood using the HIV rapid test
DetermineHIV-1/2/O (Abbott Laboratories, Abbott Park, IL)
following voluntary counseling and testing. The diagnosis
of HIV negative with an appointment for a further rapid
testing 3 months later was given to the patient following
a negative initial test. Positive samples were transported in
the Infection Prevention and Control research laboratory
at the Nelson R Mandela School of Medicine, UKZN, and
were subsequently retested by a medical technologist using
a second HIV rapid test SmartCheck test (World Diagnostics
Inc., USA). A diagnosis of HIV positive was reported to the
participants only if both rapid tests were positive. Samples
that showed discordant results were further evaluated with a
third rapid test Uni-Gold Recombigen HIV (Trinity Biotech
PLC,USA), and only two positive test results were interpreted
as a positive diagnosis for HIV.
As part of the routine management of the patients in the
clinic, allHIV-infected patients benefited directly fromCD4+
T cell count measurements, and CD4+ T cell counts used in
this study were obtained from patients’ medical records and
were not older than 3 months. However, at the time patients
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were evaluated for this research, HIV-1 RNA was measured
from the plasma and cell-free fraction of vaginal secretions
using Nuclisens Easyq HIV-1 assay v2.0 (BioMerieux, Lyon,
France) with a lowest detection limit of 20 copies/mL.
Absolute values of CD4+ T cell counts (cells/mm3) were
used to determine the degree or severity of immunocom-
promise following the World Health Organization (WHO)
immunological staging criteria: CD4 levels <200/mm3
(severe immunosuppression), CD4 levels 200–349/mm3
(advanced immunosuppression), and CD4 levels 350–
499/mm3 (mild immunosuppression) [15].
In addition, virological correlates (plasma HIV viral
loads) were also measured since they are potentially useful
markers of disease progression (although not reported to
be consistent markers) and have been shown by others to
increase across progressive stages of HIV infection [16]. For
the purpose of this study, plasma viremia was classified
as <20 copies/mL (below detectable level of the used test),
20–9999 copies/mL, and ≥10 000 copies/mL. We also log
transformedHIV loads for improved symmetry and included
them inmultivariate logistic regressionmodels as continuous
values.
2.5. Statistical Analyses. Data analysis was performed using
SPSS statistical software version 21.0 (SPSS Inc., Chicago, IL).
Data were expressed as means ± standard deviation (SD) for
the continuous variables and proportions (percentages) for
the categorical variables. Student’s 𝑡-test was performed to
assess differences between two means and ANOVA between
groups.When data were not normally distributed, theMann-
Whitney 𝑈 test was used. Either chi-square test with and
without trend or Fischer’s exact test was used to test the
degree of association of categorical variables.
Multiple logistic regression models were used to evaluate
the prediction capacity of each independent variable in the
occurrence of the expected condition. Unadjusted odds ratios
(ORs) were initially calculated to screen for inclusion in mul-
tivariate models; variables that exhibited at least moderate
association (𝑃 < 0.20) with the outcome were considered for
inclusion in the finalmodels.MultivariateORs (95%CI) were
computed after adjusting for confounding univariate factors.
All tests were two-sided and a𝑃 value of<0.05was considered
significant.
3. Results
Of the 200 patients enrolled with vaginal discharge syndrome
(VDS), 2 were excluded for missing results. Of the 198 par-
ticipants, 97 were HIV-infected and 101were HIV-uninfected.
This was a simple coincidence that the first 200 women who
met the eligibility criteria comprised of approximately equal
numbers of HIV positive and HIV negative.
From the 97 HIV-infected women, 52 cases of symp-
tomatic VVC were diagnosed (53.6%), while 38 cases of
symptomatic VVC were diagnosed among the 101 HIV-
uninfectedwomen (37.6%) (𝑃 = 0.032).The relative risk value
for symptomatic VVC amongst HIV-infected patients was
1.53 (95% CI: 1.04–2 𝑃 = 0.024). Table 1 depicts the baseline
characteristics of the study population.
In HIV-infected women, univariate analysis (Table 2)
showed that women’s vaginal flora with Nugent’s score <7
(𝑃 = 0.01), plasma HIV viral loads ≥10 000 copies/mL (𝑃 <
0.0001), genital HIV viral loads ≥10 000 copies/mL (𝑃 =
0.002), CD4 levels <200 cells/mm3 (𝑃 < 0.0001), and absence
of HAART (𝑃 < 0.001) were significantly associated with
symptomatic VVC. There was a linear correlation between
plasma HIV viral load and genital HIV shedding (𝑟 = 0.540;
𝑅
2
= 0.292; 𝑌 = 1.51 + 0.71 ∗ 𝑋; 𝑃 < 0.0001).
Findings have shown that HIV viral loads increased
across progressive stages of HIV-induced immunocom-
promise: CD4 count <200 cells/mm3, between 200–
349 cells/mm3 and ≥350 cells/mm3 significantly correlated







, respectively (𝑃 < 0.0001), and









Plasma HIV viral load and genital HIV viral load
significantly varied among HAART groups. Higher mean
of Log
10
HIV viral load values was shown in the plasma
(3.41 (2.8–4)Log
10
) of HIV-infected women antiretroviral
therapy (ART) näıve as compared to patients on HAART
(2.68 (2.34–3)Log
10
) (𝑃 = 0.014). Similarly, higher mean
of Log
10
HIV viral load values was also observed in the
genital tracts (2.61 (2.1–3.10)Log
10
) of HIV-infected women
antiretroviral therapy (ART) näıve as compared to patients
receiving HAART (1.67 (1.4–1.9)Log
10
) (𝑃 < 0.0001).
Bacterial vaginosis was frequent among HIV infected
women in the absence of symptomatic VVC (𝑃 = 0.01)
(Table 2). There was also a significant association between
bacterial vaginosis and higher levels of HIV RNA in the
plasma. Nugent scores between 0–3, 4–6, and 7–10 were asso-







, respectively (ANOVA, 𝑃 = 0.006). However,
higher levels of genital HIV RNA were not significantly
associated with Nugent score categories (ANOVA, 𝑃 =
0.062).
Findings showed a negative but not significant (Spear-
man’s Rho = −0.101; 𝑃 = 0.323) correlation between Log
10
levels of HIV RNA expression in plasma and absolute counts
of neutrophils in the genital fluid of the study participants.
However, there was a positive and significant correlation
(Spearman’s Rho = 0.234; 𝑅2 = 0.028; 𝑌 = 1.83 + 5.54 −
3 ∗ 𝑋; 𝑃 = 0.021) between Log
10
levels of HIV RNA
expression in the vagina and absolute counts of neutrophils
in the genital fluid of the study participants. There was also
a negative but significant association between CD4 count
stages and absolute count of neutrophils in the genital fluid:
HIV-infected women with CD4 count <200 cells/mm3 (𝑛 =
41) had an average 59.6 ± 6.6 PMN cells/5 high microscopic
fields (HMF) as compared to HIV-infected women with CD4
count>200 cells/mm3 (𝑛 = 56)whohad an average 18.1±13.8
PMN cells/5HMF (𝑃 < 0.0001).
Factors associated with symptomatic VVC in HIV
infected women are shown in Table 3 using multiple logis-
tic regression. The model showed that the occurrence
rate of symptomatic VVC increased with the severity of
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Table 1: Baseline characteristics of the study population (𝑛 = 198) who contributed symptomatic vulvovaginal candidiasis (VVC) and vaginal






Age in years, median (range) <0.0001
21 (18–24) 34 (35) 69 (68.3)
30 (25–34) 48 (49.5) 19 (18.8)
40.2 (35–46) 15 (15.5) 13 (12.9)
Major presenting symptoms 0.008
Genital itching and soreness 87 (89.7) 76 (75.3)
vaginal discharge and low abdominal pain 10 (10.3) 25 (24.7)
History of antibiotic use within the past 3 months 64 (65.9) 49 (48.5) 0.013
Condom use 25 (25.8) 14 (13.9) 0.035
Pregnancy 4 (4.1) 19 (18.8) <0.001
History of sexually transmitted infections (STIs) within the past 3 months 0.093
Vaginal discharge syndrome 42 (43.3) 36 (35.6)
Genital ulcer syndrome 13 (13.4) 7 (6.9)
No defined sexually transmitted infection 42 (43.3) 58 (57.4)
Currently isolated pathogens for STIs 0.085
Trichomonas vaginalis 15 (15.5) 16 (15.8) 0.683
Chlamydia trachomatis 7 (7.2) 4 (3.9) 0.228
Neisseria gonorrhoeae 6 (6.2) 5 (4.9) 0.516
Mycoplasma genitalium 2 (2.1) 1 (0.9) 0.456
Herpes simplex virus type 2 8 (8.3) 0 (0) 0.999
STI caused by more than 1 aetiology 13 (13.4) 17 (16.8) 0.93
No identified STI pathogen 46 (47.4) 58 (57.4) 1
Vaginal flora (Nugent’s score) 0.819
0 to 3 14 (14.4) 14 (13.9)
4 to 6 8 (8.3) 11 (10.9)
7 to 10 75 (77.3) 76 (75.3)
Absolute count of neutrophil cells in genital fluid 0.77
Score 1 42 (43.3) 41 (40.6)
Score 2 23 (23.7) 21 (20.8)
Score 3 32 (32.9) 39 (38.6)
Symptomatic vulvovaginal candidiasis 0.032
Yes 52 (53.6) 38 (37.6)
No (colonization or absence) 45 (46.4) 63 (62.4)
CD4+ T cell count (cells/mm3)
<200 41 (42.3) N/A N/A
200 to 349 32 (33) N/A N/A
≥350 24 (24.7) N/A N/A
Plasma HIV viral load (copies/mL)
≥10 000 22 (22.7) N/A N/A
20 to 9999 51 (52.6) N/A N/A
<20 24 (24.7) N/A N/A
Genital HIV viral load (copies/mL)
≥10 000 12 (12.4) N/A N/A
20 to 9999 21 (21.7) N/A N/A
<20 64 (65.9) N/A N/A







Users of highly active antiretroviral therapy
Yes 60 (61.9) N/A N/A
No 37 (38.1) N/A N/A
N/A: not applicable.
Table 2: Univariate associations between variables of interest and symptomatic vulvovaginal candidiasis among HIV-infected women (𝑛 =
97).
Variables of interest Symptomatic VVC (𝑛 = 52) VVC colonization (𝑛 = 45) P value
𝑛 (%) 𝑛 (%)
Age in years, median (range) 0.484
21 (18–24) 21 (40.4) 13 (28.9)
30 (25–34) 24 (46.2) 24 (53.3)
40.2 (35–46) 7 (13.5) 8 (17.8)
Major presenting complains 0.362
Vaginal discharge 4 (7.7) 6 (13.3)
Genital itching and soreness 48 (92.3) 39 (86.7)
History of antibiotic use within the past 3 months 36 (69.2) 28 (62.2) 0.467
No history of condom use 42 (80.8) 30 (66.7) 0.113
History of sexually transmitted infections within the past 3 months 0.312
Vaginal discharge syndrome 18 (34.6) 24 (53.3)
Genital ulcer syndrome 1 (1.9) 1 (2.2)
Mixed sexually transmitted infections 7 (13.5) 4 (8.9)
No defined sexually transmitted infections 26 (50) 16 (36)
Currently isolated pathogens for STIs 0.153
Trichomonas vaginalis 5 (9.6) 10 (22.2) 0.07
Chlamydia trachomatis 1 (1.9) 6 (13.3) 0.046
Neisseria gonorrhoeae 3 (5.8) 3 (6.7) 0.612
Mycoplasma genitalium 1 (1.9) 1 (2.2) 0.76
Herpes simplex virus type 2 5 (9.6) 3 (6.7) 0.93
STI caused by more than 1 aetiology 9 (17.3) 4 (8.9) 0.583
No STI pathogen identified 28 (53.8) 18 (40) 1
Vaginal flora (Nugent’s scores) 0.01
less than 7 (BV negative) 17 (32.7) 5 (11.1)
≥7 (BV positive) 35 (67.3) 40 (88.9)
Pregnancy 4 (7.7) 0 (0) 0.057
Plasma HIV viral load (VL) categories <0.0001
≥10000 copies 19 (36.5) 3 (6.7)
20–9999 copies 28 (53.8) 23 (51.1)
<20 copies 5 (9.6) 19 (42.2)
Genital HIV viral load (VL) categories 0.002
≥10000 copies 12 (23.1) 0 (0)
20–9999 copies 12 (23.1) 9 (20)
<20 copies 28 (53.8) 36 (80)
CD4+ T cell counts <0.0001
<200 cells 30 (57.7) 11 (24.4)
200–349 cells 17 (32.7) 15 (33.3)
≥350 cells 5 (9.6) 19 (42.2)
Therapy groups <0.001
Patients on antiretroviral therapy 26 (50) 34 (75.6)
Patients not receiving antiretroviral therapy 26 (50) 11 (24.4)
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Table 3: Determinants of symptomatic vulvovaginal candidiasis among HIV-infected women.
Independent variables 𝐵 Coefficient Standard error Wald chi-square OR (95% CI) 𝑃 value
CD4+ T cell groups
<200 cells 4.1 0.971 17.847 60.3 (9–134.8) <0.0001
200–349 cells 2.186 0.901 5.886 8.9 (1.5–17.36) 0.015
≥350 cells Referent 1
Vaginal Flora (Nugent’s scores)
less than 7 (BV negative) 3.143 0.954 10.844 23.2 (3.6–50.13) <0.001
≥7 (BV positive) Referent 1
Therapy groups
Patients not receiving antiretroviral therapy 1.251 0.573 4.768 3.5 (1.1–10.7) 0.029
Patients on antiretroviral therapy Referent 1
Constant −3.13 0.904 11.981 <0.001
Adjusted for previous history of sexually transmitted infections (STIs), presence of current STIs, history of condom use, pregnancy, and presenting symptoms.
HIV-induced immunosuppression. Adjusted odds ratio val-
ues were 9 (𝑃 = 0.015) and 60 (𝑃 < 0.0001), respectively,
during advanced (CD4+ T cells = 200–349/mm3) and severe
(CD4+ T cells <200/mm3) stages of HIV-induced immuno-
suppression. In addition, women not receiving HAART were
4-fold more likely (𝑃 = 0.029) to develop symptomatic
VVC than women on HAART. Findings also showed that
the probability of developing symptomatic VVC increased
with the presence of higher levels of HIV RNA in the blood
(approximately 100-fold higher for HIV positive women with
plasma HIV RNA load ≥10 000 copies/mL (𝑃 < 0.0001)).
There was a significant negative association between the
presence of bacterial vaginosis (Nugent score 7–10) and
symptomatic VVC as depicted in Table 3.
In HIV negative women, however, after adjusting for
univariate factors that exhibited at least moderate association
(𝑃 < 0.20) with symptomatic VVC (Table 4), only pregnancy
was significantly associatedwith symptomatic VVC (OR= 4.1
95% CI 1.3–10.5, 𝑃 = 0.011).
4. Discussion
Findings from this study confirmed previously published
reports on symptomatic VVC as being significantly more
prevalent among HIV infected than HIV uninfected women
[7, 8]. Whilst some studies have shown the association
between low CD4+ T-lymphocyte counts and symptomatic
VVC [4, 17], our results provide an additional body of
evidence that low CD4+ T-lymphocyte counts, particularly
CD4+ T cells <200/mm3, are significantly associated with
symptomatic VVC. In 2006, Beltrame et al. reported that can-
didal vaginal colonization, a precursor of vaginitis, develops
when CD4+ T-lymphocyte counts fall to ≤100 cells/𝜇L in the
course of HIV infection [4]. Prior to this report, Duerr et al.
published on the rates of candidal vaginal colonization and
symptomatic VVC as being similar among nonimmunocom-
promised HIV-positive women and HIV-negative women
[17]. According to these authors, elevated rates of yeast
colonization and vaginitis were not observed among their
cohort of HIV-infected women before immune compromise.
However, rates of vaginal colonization and symptomaticVVC
were seen to increase with immune compromise, especially
at CD4 counts below 200 cells/mm3 [17]. In 2000, Shifrin
et al. reported that HIV-positive women with a CD4 count
less than 200 cells/mm3 had an increase of 8.2 times in
the incidence of symptomatic vulvovaginal candidiasis. They
suggested that womenwith lowCD4 counts should be closely
monitored for the development of symptomatic VVC prior
to the development of symptoms independent of candida
colonization status [18].
However, in 2003, Ohmit et al. reported that the preva-
lence of symptomatic VVC, although higher among HIV-
infectedwomen, did not significantly differ byHIV serostatus
of the participants at baseline [19]. However, the authors
found that during follow-up visits, the rate of acquisition
of symptomatic VVC was significantly higher among HIV-
infected women as compared to HIV-uninfected women.
Furthermore, whilst Ohmit et al. identified the level of HIV-
associated immunodeficiency (measured by CD4+ T cell
counts) as not significantly associated with increased odds
for symptomatic VVC, the authors found, however, that
odds of symptomatic VVC increased by >2-fold for women
whose plasma HIV load was >1000 copies/mL. They found
an increase of 11% to 14% for every Log
10
increase in plasma
HIV viral load [19]. Prior to this report, Sobel et al. found out
that higher HIV loads rather than lower CD4+ T-lymphocyte
counts were associated with statistically significant increased
odds for both persistent candidal vaginal colonization and
symptomatic VVC [5]. However, the study by Sobel et al. only
found an association between plasma HIV viral load and the
proportion of Candida infections that were non-C. albicans,
not the absolute prevalence of symptomatic VVC [5].
Data from the present study demonstrated that plasma
HIV RNA levels were significantly associated with symp-
tomatic VVC in HIV positive women. Compared with
patients whose plasma HIV load was suppressed below the
detectable level (<20 copies/mL), cases of symptomatic VVC
increased with an increase of plasmaHIV load. Plausible bio-
logical reasons why blood HIV viral loads can correlate with
symptomatic VVC have been published by others. Following
a cross-sectional study on oral candidiasis, Gottfredsson
et al. hypothesized that high level of plasma HIV-1 can
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Table 4: Univariate associations between variables of interest and symptomatic vulvovaginal candidiasis (VVC) among HIV-uninfected
women (𝑛 = 101).
Variables of interest Symptomatic VVC (𝑛 = 38) VVC colonization (𝑛 = 63) P value
𝑛 (%) 𝑛 (%)
Age in years, median (range) 0.705
21 (18–24) 26 (68.4) 43 (68.3)
30 (25–34) 6 (15.8) 13 (20.6)
40.2 (35–46) 6 (15.8) 7 (11.1)
History of antibiotic use within the past 3 months 17 (44.7) 32 (50.8) 0.555
No history of condom use 35 (92.1) 52 (82.5) 0.178
History of sexually transmitted infections within the past 3 months 0.504
Vaginal discharge syndrome 14 (36.8) 22 (34.9)
Genital ulcer syndrome 0 (0) 2 (3.2)
Mixed sexually transmitted infections 3 (7.9) 2 (3.2)
No defined sexually transmitted infections 21 (55.3) 37 (58.7)
Currently isolated pathogens for STIs 0.377
Trichomonas vaginalis 5 (13.2) 11 (17.5) 0.333
Chlamydia trachomatis 2 (5.3) 2 (3.2) 0.841
Neisseria gonorrhoeae 2 (5.3) 3 (4.8) 0.835
Mycoplasma genitalium 0 (0) 1 (1.6) 1
Herpes simplex virus type 2 0 (0) 0 (0) 0.053
STI caused by more than 1 aetiology 3 (7.9) 14 (22.2) 1
No STI pathogen identified 26 (68.4) 14 (22.2) 1
Vaginal flora (Nugent’s scores) 0.08
Less than 7 (BV negative) 13 (34.2) 12 (19)
≥7 (BV positive) 25 (65.8) 51 (81)
Pregnancy 12 (31.6) 7 (11.1) 0.011
BV: bacterial vaginosis.
suppress local mucosal immune mechanisms independently
of systemic cell-mediated immunity, leading to mucosal
colonization with Candida species [20]. The authors also
speculated that controlling the replication of HIV-1 could
possibly restore local mucosal immune functions. Similarly,
during an in vitro analysis, Gruber et al. reported that high
plasma and therefore salivary or oral HIV-1 load might
promote virulence ofC. albicans at oralmucosal surfaces [21].
In the present study, we found a significant linear correlation
between plasma HIV viral load and genital HIV shedding.
We also found that HIV viral loads (in plasma and vagina)
increased across progressive stages ofHIV-induced immuno-
compromise by CD4+ T cell stages.We can therefore hypoth-
esize that during advanced HIV infection (as measured by
low CD4+ T cell levels) with subsequently observed higher
HIV viral loads, HIV particles might change the vaginal
environment, hence promoting virulence of Candida species
by switching from its nonpathogenic form into a filamentous
form that causes symptomatic VVC.We can further speculate
that because ART-naı̈ve HIV-infected women were more
likely able to develop symptomatic VVC than women on
HAART, controlling the replication of HIV by using HAART
could possibly restore local mucosal immune functions in
the vagina. This suggests that high levels of plasma HIV
load could suppress genital mucosal immune mechanisms
independently of systemic cell-mediated immunity, leading
to symptomatic VVC. Further studies are required to confirm
this hypothesis. Although during our multivariate logistic
regression models, genital HIV shedding was not identified
as a significant determinant of symptomatic VVC, increased
genital HIV load was, however, shown to correlate with
symptomatic VVC only in univariate analysis. This could
be explained by the fact that HIV load was only measured
from the cell-free fraction of cervicovaginal fluid (HIV
RNA expression). HIV is more readily detected in the cell-
associated component of genital secretions (HIV DNA) than
in the cell-free component. It is possible that the cell-
associated fraction of vaginal secretions could reflect better
shedding of HIV infected cells from the vagina, while the
cell-free fraction may only represent HIV released locally
by actively replicating cells. Whilst a univariate association
was shown between genital HIV load and symptomatic VVC,
there was a positive and significant correlation between
Log
10
levels of genital HIV RNA expression and absolute
counts of neutrophils in the genital fluid. In addition, due
to the inverse relationship between CD4 count and absolute
neutrophil count shown in our study, it can be postulated that
this is the result of increased HIV shedding in the vagina
with a concomitant inflammatory response in the setting of
increasing immune suppression. Another study is required to
ascertain this hypothesis.
Based on data from a human life challengemodel, Fidel Jr.
et al. hypothesized that following the interaction of Candida
with vaginal epithelial cells, symptomatic VVC was associ-
ated with signals that promoted a nonprotective inflamma-
tory leukocyte response and concomitant clinical symptoms.
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They indicated that neutrophils contribute to the pathogene-
sis and local inflammation in symptomatic VVC [22].
There was a significant negative association between the
presence of BV and symptomatic VVC. A high prevalence
of BV was diagnosed among both HIV positive and HIV
negative women. The rate of BV has been always reported
to be very high in the South African province of KwaZulu-
Natal. In 1996, Govender et al., during a study on BV and
associated pregnancy outcomes among asymptomatic preg-
nant women attending antenatal clinic at King Edward VIII
hospital in Durban/KwaZulu-Natal, reported a prevalence
of 52% for BV, and BV was the leading lower genital tract
infection according to the authors [23]. In 2002, Moodley
et al. during a study at Hlabisa Health District in northern
KwaZuluNatal found the prevalence of BV to be 70% among
their 598 enrolled women [24]. BV is known as a syndrome
characterized by imbalance of the vaginal ecosystem. It can
be postulated that in the KwaZulu-Natal province of South
Africa, anecdotal reports of the excessive use of topically
applied substances in the vagina with antimicrobial effects
interferes with the lactobacilli. The depletion of lactobacilli
may limit the production of hydrogen peroxide. Vallone et al.
postulated that low vaginal pH inhibits CD4 lymphocyte
activation and reduces HIV target cells in the vagina, while
elevated vaginal pH may enhance HIV adherence to vaginal
eukaryotic cells [25]. In this present study, although BV was
prevalent among both HIV positive and HIV negative, there
was a significant association between BV and higher expres-
sion of HIV RNA in the plasma of HIV-infected women. Our
findings have also shown a significant association between
the composition of the vaginal microbiota and the develop-
ment of symptomaticVVC inHIV infectedwomen.Using the
Nugent score to assess the degree of alteration of the vaginal
flora, symptomatic VVC was significantly associated with a
score of <7. These findings strongly support the hypothesis
that symptomatic VVC is usually associated with a normal
vaginal pH (pH < 4.5), while BV is established when pH of
the vaginal fluid becomes >4.5. In addition, these findings
are also in keeping with results from Moodley et al. who
foundout that Yeast colonization and symptomaticVVCwere
inversely related to Nugent’s scores [24].
In addition to low Nugent score, another factor that was
identified as being significantly associated with symptomatic
VVC was pregnancy, particularly among HIV-uninfected
women.This findingwas consistent withwhat has been found
elsewhere [1].
Although HIV-uninfected women with symptomatic
VVC reported a history of antibiotic use within the past
3 months prior to the clinic visit more than women with-
out symptomatic VVC, this difference was not statistically
significant. The use of broad spectrum antibiotic has been
extensively reported from the literature as a determinant
of symptomatic VVC [1]. The fact that patients have been
asked if they received any antibiotic in the last 3 months may
not provide an accurate information as some patients might
forgot or could not differentiate antibiotics from other types
of medicines that they received.
Although the presence of concurrent lower genital tract
pathogens were not shown to be significantly associated
with symptomatic VVC, there was a negative association
between the presence of symptomatic VVC and vaginitis
caused by Trichomonas vaginalis. Moodley et al. reported
that T. vaginalis was prevalent in patients with all levels of
abnormal vaginal flora (bacterial vaginosis score of Gram
stain >4) suggesting that this pathogen might contribute to
the change in vaginal flora leading to BV [24]. The authors
further identified that the presence of yeasts on microscopy
was inversely related to the level of ecologic disturbance.
They argued that BV environment is not conducive to yeast
multiplication, and yeast vaginitis therefore does not occur
frequently in the presence of both BV and T. vaginalis [24].
5. Limitations
A small sample size needs to be underlined as a first limi-
tation. The fact that CD4 counts obtained from the patient
medical records might be at least 3 months old presents a
limitation in the interpretation of our results, in that the
degree of immune suppression may have been over- or
underestimated. However, in our study there was a significant
negative association betweenCD4 counts andHIV viral loads
in plasma (𝑃 < 0.0001). A further bias in the study is the
fact that we used patients’ records of ARV prescriptions and
patient interviews as a proxy for ARV treatment adherence.
The latter is often subjective. Measurement of drug levels is a
more objective test of adherence. However, this was not done
in our study.
Although we assessed the history of previous vaginal
discharge syndrome, this was not conclusive of symptomatic
VVCandhence could not establish possible cases of recurrent
VVC. Finally, we prevented colinearities in our logistic
models by not including variables that were highly correlated,
but the 95% confidence intervals around the odds ratios were
slightly wide for certain variables.Thismight be due to poten-
tial variability observed during the measurement of CD4+
T cells and HIV loads. Despite these limitations, findings
from this study add on the existing body of evidence on
the correlation between HIV-induced immunocompromise
and the presence of symptomatic VVC. Commencing HIV-
infectedwomen onHAART could prevent new incident cases
of symptomatic VVC.
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